Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
Conditions
Interventions
Pamrevlumab
Placebo
+1 more
Locations
52
United States
Arkansas Children's Hospital
Little Rock, Arkansas, United States
Children's Hospital Los Angeles
Los Angeles, California, United States
University of California Davis Children's Hospital
Sacramento, California, United States
University of California San Diego Health
San Diego, California, United States
Children's Hospital Colorado
Aurora, Colorado, United States
University of Florida Health Shands Hospital
Gainesville, Florida, United States
Start Date
March 3, 2021
Primary Completion Date
June 12, 2023
Completion Date
December 14, 2023
Last Updated
August 26, 2024
NCT06817382
NCT06839469
NCT07037862
NCT07160634
NCT06450639
NCT05016908
Lead Sponsor
Kyntra Bio
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions